First Time Loading...

Societal CDMO Inc
NASDAQ:SCTL

Watchlist Manager
Societal CDMO Inc Logo
Societal CDMO Inc
NASDAQ:SCTL
Watchlist
Price: 1.08 USD -0.92% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). [ Read More ]

The intrinsic value of one SCTL stock under the Base Case scenario is 1.3 USD. Compared to the current market price of 1.08 USD, Societal CDMO Inc is Undervalued by 17%.

Key Points:
SCTL Intrinsic Value
Base Case
1.3 USD
Undervaluation 17%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Societal CDMO Inc

Backtest SCTL Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling SCTL stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Societal CDMO Adjusts Guidance Amid Growth
2023-Q3 Earnings Call

Societal CDMO Adjusts Guidance Amid Growth

Societal CDMO reported a revenue jump to $23.6 million for Q3 2023, up from $21.6 million the previous year, citing increased demand for Verapamil products. Despite the rise, a net loss widened to $4.6 million ($0.05 per diluted share) from $3.3 million ($0.06 per diluted share), and adjusted EBITDA fell to $2.8 million from $3.8 million. For the nine months, revenue inched up to $66.9 million from $65.9 million, while net loss also grew to $12.5 million. The company is streamlining operations, expecting to reduce annualized costs by $5.5 million and revising 2023 revenue guidance to $92-$94 million, with adjusted EBITDA projected at $11.5-$13 million.

Financials

Balance Sheet Decomposition
Societal CDMO Inc

Current Assets 53.5m
Cash & Short-Term Investments 8.1m
Receivables 29.4m
Other Current Assets 16m
Non-Current Assets 100m
PP&E 54.8m
Intangibles 43.3m
Other Non-Current Assets 1.9m
Current Liabilities 50m
Accounts Payable 1.3m
Accrued Liabilities 11.4m
Other Current Liabilities 37.3m
Non-Current Liabilities 44.8m
Long-Term Debt 339k
Other Non-Current Liabilities 44.5m
Efficiency

Earnings Waterfall
Societal CDMO Inc

Revenue
94.6m USD
Cost of Revenue
-76.5m USD
Gross Profit
18.1m USD
Operating Expenses
-21.7m USD
Operating Income
-3.6m USD
Other Expenses
-9.7m USD
Net Income
-13.3m USD

Free Cash Flow Analysis
Societal CDMO Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

SCTL Profitability Score
Profitability Due Diligence

Societal CDMO Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

Positive 3-Years Revenue Growth
Positive Gross Profit
ROIC is Increasing
Positive Revenue Growth Forecast
30/100
Profitability
Score

Societal CDMO Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

SCTL Solvency Score
Solvency Due Diligence

Societal CDMO Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Long-Term Solvency
Short-Term Solvency
44/100
Solvency
Score

Societal CDMO Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SCTL Price Targets Summary
Societal CDMO Inc

Wall Street analysts forecast SCTL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SCTL is 1.12 USD with a low forecast of 1.11 USD and a high forecast of 1.16 USD.

Lowest
Price Target
1.11 USD
3% Upside
Average
Price Target
1.12 USD
4% Upside
Highest
Price Target
1.16 USD
7% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

SCTL Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

SCTL Price
Societal CDMO Inc

1M 1M
+1%
6M 6M
+130%
1Y 1Y
-9%
3Y 3Y
-61%
5Y 5Y
-79%
10Y 10Y
-84%
Annual Price Range
1.08
52w Low
0.3
52w High
1.19
Price Metrics
Average Annual Return 21.99%
Standard Deviation of Annual Returns 143.4%
Max Drawdown -98%
Shares Statistics
Market Capitalization 113.2m USD
Shares Outstanding 105 573 000
Percentage of Shares Shorted 0.17%

SCTL Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Societal CDMO Inc Logo
Societal CDMO Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

113.2m USD

Dividend Yield

0%

Description

Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The company is headquartered in Exton, Pennsylvania and currently employs 258 full-time employees. The company went IPO on 2014-03-07. Societal CDMO is principally focused on solving various manufacturing problems. The company is a CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. In addition to its experience in handling Drug Enforcement Agency (DEA) controlled substances and developing and manufacturing modified-release dosage forms, the Company has the ability to deliver on its clients pharmaceutical development and manufacturing projects. The company conducts its operations in Gainesville, Georgia and San Diego, California.

Contact

PENNSYLVANIA
Exton
1 E. Uwchlan Ave, Suite 112
+17705348239.0
https://ir.recropharma.com/

IPO

2014-03-07

Employees

258

Officers

Executive Chairman of the Board
Mr. Wayne B. Weisman J.D.
President, CEO & Director
Mr. J. David Enloe Jr.
Senior VP & CFO
Mr. Ryan D. Lake CPA
Senior VP & COO
Mr. Marshall Rizzo M.B.A.
Senior VP & Chief Scientific Officer
Mr. Richard Sidwell Ph.D.
Vice President of Sales
Ms. Cristin Grove
Show More
Senior VP & Chief People Officer
Ms. Erica Raether M.A.
Show Less

See Also

Discover More
What is the Intrinsic Value of one SCTL stock?

The intrinsic value of one SCTL stock under the Base Case scenario is 1.3 USD.

Is SCTL stock undervalued or overvalued?

Compared to the current market price of 1.08 USD, Societal CDMO Inc is Undervalued by 17%.